MA44110B1 - Polythérapie - Google Patents

Polythérapie

Info

Publication number
MA44110B1
MA44110B1 MA44110A MA44110A MA44110B1 MA 44110 B1 MA44110 B1 MA 44110B1 MA 44110 A MA44110 A MA 44110A MA 44110 A MA44110 A MA 44110A MA 44110 B1 MA44110 B1 MA 44110B1
Authority
MA
Morocco
Prior art keywords
cancer
alaninyl
benzoxy
combination therapy
phenyl
Prior art date
Application number
MA44110A
Other languages
English (en)
Other versions
MA44110A (fr
Inventor
Hugh Griffith
Original Assignee
NuCana plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NuCana plc filed Critical NuCana plc
Priority claimed from PCT/GB2016/054018 external-priority patent/WO2017109486A1/fr
Publication of MA44110A publication Critical patent/MA44110A/fr
Publication of MA44110B1 publication Critical patent/MA44110B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Cette invention concerne une association de gemcitabine- [phényl-benzoxy-l-alaninyl)]-phosphate (nom chimique: 2 '-désoxy -2 ', 2 '-difluoro-d-cytidine -5 '-o- [phényl (benzoxy-l-alaninyl) ] phosphate) (nuc -1031) et un agent anticancéreux à base de platine choisi parmi le cisplatine, le picoplatine, le lipoplatine et le triplatine. Les combinaisons sont utiles dans le traitement du cancer et en particulier le cancer de la vésicule et des voies biliaires et le cancer de la vessie.
MA44110A 2015-12-23 2016-12-21 Polythérapie MA44110B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/GB2015/054158 WO2017109444A1 (fr) 2015-12-23 2015-12-23 Traitement combiné
PCT/GB2016/054018 WO2017109486A1 (fr) 2015-12-23 2016-12-21 Polythérapie
EP16820005.3A EP3393478B1 (fr) 2015-12-23 2016-12-21 Polythérapie

Publications (2)

Publication Number Publication Date
MA44110A MA44110A (fr) 2018-10-31
MA44110B1 true MA44110B1 (fr) 2020-03-31

Family

ID=55069010

Family Applications (1)

Application Number Title Priority Date Filing Date
MA44110A MA44110B1 (fr) 2015-12-23 2016-12-21 Polythérapie

Country Status (6)

Country Link
US (1) US20190381084A1 (fr)
KR (1) KR102566461B1 (fr)
AU (1) AU2015418015B2 (fr)
CA (1) CA3008769A1 (fr)
MA (1) MA44110B1 (fr)
WO (1) WO2017109444A1 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE033335T2 (en) 2012-11-16 2017-11-28 Univ College Cardiff Consultants Ltd RP / SP gemcitabine [phenyl (benzyloxy-L-alaninyl)] phosphate mixture
MY186584A (en) 2014-06-25 2021-07-28 Nucana Biomed Ltd Formulation comprising a gemcitabine-prodrug
ES2948660T3 (es) 2014-06-25 2023-09-15 NuCana plc Profármacos de gemcitabina
GB201417644D0 (en) 2014-10-06 2014-11-19 Nucana Biomed Ltd Method of separating phosphate diastereoisomers
KR20180063075A (ko) 2015-10-05 2018-06-11 뉴카나 피엘씨 조합 요법
SG11201804774YA (en) 2015-12-11 2018-07-30 NuCana plc Diastereoselective synthesis of phosphate derivatives and of the gemcitabine prodrug nuc-1031
GB201522771D0 (en) 2015-12-23 2016-02-03 Nucana Biomed Ltd Crystalline form of a phosphate derivative
TWI787201B (zh) 2016-08-31 2022-12-21 日商富士軟片股份有限公司 抗腫瘤劑、抗腫瘤效果增強劑及抗腫瘤用套組
GB201713914D0 (en) * 2017-08-30 2017-10-11 Nucana Biomed Ltd Combination therapy
AU2021373619A1 (en) * 2020-11-03 2023-06-15 Cornerstone Pharmaceuticals, Inc. Therapeutic methods and compositions for treating biliary tract cancer using devimistat

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0317009D0 (en) 2003-07-21 2003-08-27 Univ Cardiff Chemical compounds
EA201792509A1 (ru) * 2015-05-14 2018-05-31 НУКАНА ПиЭлСи Лечение рака

Also Published As

Publication number Publication date
KR102566461B1 (ko) 2023-08-14
AU2015418015B2 (en) 2021-12-09
CA3008769A1 (fr) 2017-06-29
AU2015418015A1 (en) 2018-07-05
WO2017109444A1 (fr) 2017-06-29
KR20180096697A (ko) 2018-08-29
MA44110A (fr) 2018-10-31
US20190381084A1 (en) 2019-12-19

Similar Documents

Publication Publication Date Title
MA44110B1 (fr) Polythérapie
PH12018501339A1 (en) Combination therapy
PH12018500691A1 (en) Combination therapy
MX2021007468A (es) Compuestos que participan en la union cooperativa y usos de los mismos.
CY1118216T1 (el) Μεθοδοι αγωγης καρκινου
PH12014501106A1 (en) Rnai agents, compositions and methods of use thereof for treating transthyretin (ttr) associated diseases
TW200716141A (en) Compositions and methods for treatment for neoplasms
BR112016029041A2 (pt) terapia de combinação com inibidores de glutaminase
MX2015011752A (es) Metodos para tratar cancer de pulmon.
EA200970891A1 (ru) Генетические варианты chr2 и chr16 в качестве маркеров для применения при оценке риска, диагностировании, прогнозировании и лечении рака молочной железы
PH12015501744B1 (en) Therapeutic and diagnostic target for cancer comprising dll3 binding reagents
MX2017016134A (es) Aril dihidro-2h-benzo[b][1,4]oxazina sulfonamida y compuestos relacionados para uso como agonistas de rory y el tratamiento de enfermedad.
MA39725B1 (fr) Compositions pharmaceutiques de composés thérapeutiquement actifs
WO2008120098A3 (fr) Promédicaments peptidiques
MX2017013074A (es) Metodos y composiciones para prediccion de eficacia terapeutica de tratamientos contra el cancer y prognosis del cancer.
EA201990567A1 (ru) Комбинированная терапия с ингибиторами глутаминазы
MX2010009782A (es) Tratamientos antitumorales mejorados.
WO2007124314A3 (fr) Utilisation de transporteurs de cations organiques pour le diagnostic et le traitement du cancer
MA43294A1 (fr) Sels et promédicaments de 1-méthyl -d-tryptophane
MX2018012545A (es) Reactivos para el tratamiento de distrofia muscular oculofaríngea (opmd) y su uso.
IN2014DN04596A (fr)
MX2019008919A (es) Moduladores de rorgamma y usos de los mismos.
MX2019006685A (es) Combinacion terapeutica para el tratamiento de cancer.
WO2023097197A3 (fr) Compositions et méthodes pour évaluer l'efficacité d'une administration de polynucléotides et d'une thérapie anticancéreuse
Spry et al. Resistance Training and Cancer Survival/In Reply